The aim of this open pilot study was to establish the profile of tolerability and clinical response of salbutamol (albuterol) in a cohort of young children affected by type II spinal muscular atrophy (SMA). Twenty-three children between 30 months and 6 years of age were treated with salbutamol (2 mg three times a day) for 1 year. All children were longitudinally assessed using the Hammersmith motor functional scale 6 months before treatment started (T0), at baseline (T1) and 6 and 12 months later. There was no significant change in function between T0 and T1 assessments, but the functional scores recorded after 6 and 12 months of treatment were significantly higher than those recorded at baseline (p = 0.006). Our results suggest that salbutamol may be beneficial to SMA patients without producing any major side effect. Larger prospective randomized, double-blind, placebo controlled trials are needed to confirm these preliminary findings. © 2008 Elsevier B.V. All rights reserved.
Pane, M., Staccioli, S., Messina, S., D'Amico, A., Pelliccioni, M., Mazzone, E. S., Cuttini, M., Alfieri, P., Battini, R., Main, M., Muntoni, F., Bertini, E. S., Villanova, M., Mercuri, E. M., Daily salbutamol in young patients with SMA type II, <<NEUROMUSCULAR DISORDERS>>, 2008; 18 (7): 536-540. [doi:10.1016/j.nmd.2008.05.004] [https://hdl.handle.net/10807/260311]
Daily salbutamol in young patients with SMA type II
Pane, Marika;Mazzone, Elena Stacy;Battini, Roberta;Bertini, Enrico Silvio;Mercuri, Eugenio Maria
2008
Abstract
The aim of this open pilot study was to establish the profile of tolerability and clinical response of salbutamol (albuterol) in a cohort of young children affected by type II spinal muscular atrophy (SMA). Twenty-three children between 30 months and 6 years of age were treated with salbutamol (2 mg three times a day) for 1 year. All children were longitudinally assessed using the Hammersmith motor functional scale 6 months before treatment started (T0), at baseline (T1) and 6 and 12 months later. There was no significant change in function between T0 and T1 assessments, but the functional scores recorded after 6 and 12 months of treatment were significantly higher than those recorded at baseline (p = 0.006). Our results suggest that salbutamol may be beneficial to SMA patients without producing any major side effect. Larger prospective randomized, double-blind, placebo controlled trials are needed to confirm these preliminary findings. © 2008 Elsevier B.V. All rights reserved.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
